Evidence map›Paper›PMID 30305739›Full record

ArticleNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2018

The abuse-related effects of pyrrolidine-containing cathinones are related to their potency and selectivity to inhibit the dopamine transporter.

Brenda M Gannon, Michael H Baumann, Donna Walther, Cristian Jimenez-Morigosa, Agnieszka Sulima, Kenner C Rice, Gregory T Collins

Open access · bronzeAbstract read
In one paragraph

Article in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed, 1 pooled it
6.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

67 citing papers in PubMed, 1 synthesis or guideline pooled it, 93 citations in OpenAlex.

  1. Synthetic Cathinones and Neurotoxicity Risks: A Systematic Review.International journal of molecular sciences · 2023
    Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article

7 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Brenda M GannonDepartment of Pharmacology, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
Michael H BaumannDesigner Drug Research Unit, Intramural Research Program, NIDA, NIH, Baltimore, MD, USA.
Donna WaltherDesigner Drug Research Unit, Intramural Research Program, NIDA, NIH, Baltimore, MD, USA.
Cristian Jimenez-MorigosaDesigner Drug Research Unit, Intramural Research Program, NIDA, NIH, Baltimore, MD, USA.
Agnieszka SulimaMolecular Targets and Medications Discovery Branch, Intramural Research Program, NIDA and NIAAA, Bethesda, MD, USA.
Kenner C RiceMolecular Targets and Medications Discovery Branch, Intramural Research Program, NIDA and NIAAA, Bethesda, MD, USA.
Gregory T CollinsDepartment of Pharmacology, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA. CollinsG@uthscsa.edu.
National Institute on Drug Abuse · USTarget (United States) · USSouth Texas Veterans Health Care System · USThe University of Texas Health Science Center at San Antonio · US

Funding

Training in Drug Abuse Research: Behavior and NeurobiologyT32DA031115 · NIDA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI CHARLES P FRANCE · 2011 to 2026
$5.2M
Medicinal Chemistry of Drugs Acting on Biogenic Amine ReceptorsZIADA000532 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI RICE, KENNER · 2009 to 2020
$4.5M
Bath Salts: Abuse-related and Toxic EffectsR01DA039146 · NIDA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Gregory Collins · 2015 to 2026
$4.0M
IMPROVING HEALTH CARE UTILIZATION IN HIV+ DRUG USERSK23DA000523 · NIDA · JOHNS HOPKINS UNIVERSITY · PI GEBO, KELLY A · 2001 to 2005
$794k
Studies on MDMA and Related CompoundsZ01DA000523 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI ROTHMAN, RICHARD · 2008 to 2008
$199k
Intramural NIH HHS Z01 DA000523NIDA NIH HHS K23 DA000523NIDA NIH HHS R01 DA039146NIDA NIH HHS T32 DA031115
6 · The paper itself

Abstract

Synthetic cathinones are common constituents of abused "bath salts" preparations and represent a large family of structurally related compounds that function as cocaine-like inhibitors or amphetamine-like substrates of dopamine (DAT), norepinephrine (NET), and serotonin (SERT) transporters. Preclinical evidence suggests that some cathinones (e.g., MDPV and α-PVP) are more effective reinforcers than prototypical stimulant drugs of abuse, such as cocaine or methamphetamine. Although the reinforcing potency of these cathinones is related to their potency to inhibit DAT, less is known about the pharmacological determinants of their unusually high reinforcing effectiveness. To this end, we tested the hypothesis that reinforcing effectiveness of cathinone stimulants is positively correlated with their selectivity for DAT relative to SERT. Uptake inhibition assays in rat brain synaptosomes were used to directly compare the potency of MDPV, MDPBP, MDPPP, α-PVP, α-PPP, and cocaine at DAT, NET, and SERT, whereas intravenous self-administration in rats was used to quantify relative reinforcing effectiveness of the drugs using progressive ratio (PR) and behavioral economic procedures. All cathinones were more potent at DAT than NET or SERT, with a rank order for selectivity at DAT over SERT of α-PVP > α-PPP > MDPV > MDPBP > MDPPP > cocaine. These synthetic cathinones were more effective reinforcers than cocaine, and the measures of reinforcing effectiveness determined by PR and demand curve analyses were highly correlated with selectivity for DAT over SERT. Together, these studies provide strong and convergent evidence that the abuse potential of stimulant drugs is mediated by uptake inhibition at DAT, with activity at SERT serving as a negative modulator of reinforcing effectiveness.

Indexed as

Illicit DrugsAlkaloidsAnimalsBenzodioxolesCocaineConditioning, OperantDopamine Plasma Membrane Transport ProteinsDopamine Uptake InhibitorsDose-Response Relationship, DrugMalePentanonesPsychotropic DrugsPyrrolidinesRatsRats, Sprague-DawleySelf Administration1-phenyl-2-(1-pyrrolidinyl)-1-pentanoneAlkaloidsBenzodioxolescathinoneCocaineDopamine Plasma Membrane Transport ProteinsDopamine Uptake InhibitorsIllicit DrugsPentanonesPsychotropic DrugspyrrolidinePyrrolidinesSynthetic Cathinone

Identifiers

PMID30305739
PMCPMC6180085
OpenAlexW2890340690

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.